about
Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.Implementation of an intraoperative electron radiotherapy in vivo dosimetry programContribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment.Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.Practical issues regarding angular and energy response in in vivo intraoperative electron radiotherapy dosimetry.Statistical process control for electron beam monitoring.Defining Action Levels for In Vivo Dosimetry in Intraoperative Electron Radiotherapy.In vivo dosimetry in intraoperative electron radiotherapy: microMOSFETs, radiochromic films and a general-purpose linac.Quality indicators in radiation oncology: proposal of the Spanish Society of Radiation Oncology (SEOR) for a continuous improvement of the quality of care in oncologyThe contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapyUncertainties and CTV to PTV margins quantitative assessment using cone-beam CT technique in clinical application for prostate, and head and neck irradiation tumoursFailure mode and effect analysis oriented to risk-reduction interventions in intraoperative electron radiation therapy: The specific impact of patient transportation, automation, and treatment planning availability[Bone metastasis secondary to renal carcinoma diagnosed with bone scintigraphy]Retroperitoneal tumour radiotherapy: clinical improvements using kilovoltage cone beam computed tomographyTheoretical aspects of implementation of kilovoltage cone-beam CT onboard linear accelerator for image-guided radiotherapyAdjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotypeTime for radioimmunotherapy: an overview to bring improvements in clinical practiceSEOR recommendations on the use of protons
P50
Q34748629-C079C1C1-5F99-4401-A811-B5BD37AEEDC4Q35565976-57F3961E-5226-40C2-BF9C-48A20D3F30DEQ36691469-273892D4-BC80-48E6-A011-F500B879D986Q37676686-924E1626-7584-49D1-8C16-C620CA9352F4Q38802235-CA9C6300-6C98-47B3-ABDF-DDAE5385984CQ38993336-9975CF3A-D44F-4FF8-834D-4AA50CD5EA02Q39000775-AA03F10C-5BF8-4A1E-B0CA-BF7218C0DEB7Q40888777-EC8BCEFA-2A2B-4F27-940E-0889C32CF56EQ44045168-8883043B-D71C-465E-B9D9-95B5AD1C1D34Q57475434-3578304A-CF40-4AD4-BAF5-EE5063418C26Q58656934-4ED44957-581A-4DCD-86AB-10496B6570D8Q58656938-ABBF8865-59D0-4CE9-AC1F-FFD561A21744Q61730660-168B9B34-B6C8-4211-AA5C-7159D4F5CF44Q77417564-63641865-DDD1-4622-AD52-FABF990ECC19Q83690349-CE86C205-ACF6-44E9-BB95-FF9B250FCC1AQ84364335-65F61EBB-9CD2-43BC-BC37-97F1694A99CEQ87567780-6DCFAF31-2E51-4E85-81D7-A79A392C49BCQ91048669-ED01BF7F-7B3D-4BBD-A840-7099866F677FQ92584069-42DE0622-1581-423A-87B1-2F3E09CE5C97
P50
description
researcher
@en
name
C Ferrer Albiach
@en
C Ferrer Albiach
@nl
type
label
C Ferrer Albiach
@en
C Ferrer Albiach
@nl
prefLabel
C Ferrer Albiach
@en
C Ferrer Albiach
@nl
P106
P31
P496
0000-0001-9122-7646